

Psychedelic Medicinal Products – Authorised Prescriber Scheme

1. The total number of Authorised Prescribers currently approved by the TGA to prescribe 3,4-Methylenedioxymethamphetamine (MDMA) is 30*
2. The total number of Authorised Prescribers currently approved by the TGA to prescribe psilocybine is 26*
3. The total reported number of unique patients treated with MDMA under the TGA Authorised Prescriber scheme since July 2023 is 87[†]
4. The total reported number of unique patients treated with psilocybine under the TGA Authorised Prescriber scheme since July 2023 is 47[†]

*Data is current as of 16 September 2025

[†]Authorised Prescribers must submit reports to the TGA every six months for each authorisation they hold and declare the number of patients treated under each of their approvals.

An Authorised Prescriber of psychedelic medicinal products may hold an authorisation for either MDMA or psilocybine or separate authorisations for both medicinal products.

The information provided in six monthly reports is self-declared by applicants. No patient details are provided in the reports, which means potential duplications cannot be removed. Therefore, the TGA cannot guarantee the data is an accurate representation of the number of patients accessing psychedelic medicinal products. Additionally, the TGA does not hold prescription data. A single patient may be prescribed additional doses of psychedelic medicinal products as clinically necessary.

Reports are for the periods 1 January to 30 June and 1 July to 31 December and must be submitted within one month of the reporting period ending. The above data is current as of the last completed reporting period (1 January to 30 June 2025).

**Australian Government****Department of Health, Disability and Ageing
Therapeutic Goods Administration****FOI 26-2177**

Branch/Section: AEMDS/PBFT

Scope of the request:

5. Document that contains the total number of adverse events reported to the TGA associated with the prescription of 3,4,-Methylenedioxyamphetamine (MDMA) under the Authorised Prescriber scheme since July 2023
6. Document that contains the total number of adverse events reported to the TGA associated with the prescription of psilocybin under the Authorised Prescriber scheme since July 2023.'

The timeframe of the request is from 1 July 2023 to 1 August 2025.

Name of the Medicine	Total number of adverse events reported to TGA
Methylenedioxyamphetamine (MDMA)	0
Psilocybin	0